WO2023281524A1 - Placenta derived mesenchymal stromal cell secretome, process and uses thereof - Google Patents
Placenta derived mesenchymal stromal cell secretome, process and uses thereof Download PDFInfo
- Publication number
- WO2023281524A1 WO2023281524A1 PCT/IN2022/050492 IN2022050492W WO2023281524A1 WO 2023281524 A1 WO2023281524 A1 WO 2023281524A1 IN 2022050492 W IN2022050492 W IN 2022050492W WO 2023281524 A1 WO2023281524 A1 WO 2023281524A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue
- medium
- cell culture
- culture medium
- cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 210000002536 stromal cell Anatomy 0.000 title claims abstract description 11
- 230000008569 process Effects 0.000 title claims abstract description 8
- 210000002826 placenta Anatomy 0.000 title abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 9
- 230000003660 hair regeneration Effects 0.000 claims abstract description 6
- 239000006143 cell culture medium Substances 0.000 claims description 45
- 210000002966 serum Anatomy 0.000 claims description 45
- 210000001519 tissue Anatomy 0.000 claims description 29
- 108010035532 Collagen Proteins 0.000 claims description 27
- 102000008186 Collagen Human genes 0.000 claims description 27
- 108060005980 Collagenase Proteins 0.000 claims description 27
- 102000029816 Collagenase Human genes 0.000 claims description 27
- 229920001436 collagen Polymers 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 26
- 229960002424 collagenase Drugs 0.000 claims description 24
- 239000002609 medium Substances 0.000 claims description 22
- 230000001143 conditioned effect Effects 0.000 claims description 21
- 102000001708 Protein Isoforms Human genes 0.000 claims description 15
- 108010029485 Protein Isoforms Proteins 0.000 claims description 15
- 230000008859 change Effects 0.000 claims description 15
- 210000005059 placental tissue Anatomy 0.000 claims description 9
- 108090000631 Trypsin Proteins 0.000 claims description 8
- 102000004142 Trypsin Human genes 0.000 claims description 8
- 239000012588 trypsin Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 238000010899 nucleation Methods 0.000 claims description 7
- 230000008929 regeneration Effects 0.000 claims description 7
- 238000011069 regeneration method Methods 0.000 claims description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 6
- 108091068853 Homo sapiens miR-100 stem-loop Proteins 0.000 claims description 6
- 108091070493 Homo sapiens miR-21 stem-loop Proteins 0.000 claims description 6
- 108091072687 Homo sapiens miR-3191 stem-loop Proteins 0.000 claims description 6
- 210000002744 extracellular matrix Anatomy 0.000 claims description 6
- 108091008065 MIR21 Proteins 0.000 claims description 5
- 101150014058 MMP1 gene Proteins 0.000 claims description 5
- 108030001564 Neutrophil collagenases Proteins 0.000 claims description 5
- 102000056189 Neutrophil collagenases Human genes 0.000 claims description 5
- 108700004333 collagenase 1 Proteins 0.000 claims description 5
- 210000000577 adipose tissue Anatomy 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 210000003074 dental pulp Anatomy 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 230000017423 tissue regeneration Effects 0.000 claims description 3
- 230000004862 vasculogenesis Effects 0.000 claims description 3
- 108700006666 betaIG-H3 Proteins 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 abstract description 3
- 239000002679 microRNA Substances 0.000 abstract description 3
- 230000003716 rejuvenation Effects 0.000 abstract description 2
- 238000010963 scalable process Methods 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 24
- 206010052428 Wound Diseases 0.000 description 22
- 208000027418 Wounds and injury Diseases 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 238000000151 deposition Methods 0.000 description 10
- 230000008021 deposition Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 206010029113 Neovascularisation Diseases 0.000 description 9
- 238000013508 migration Methods 0.000 description 9
- 230000005012 migration Effects 0.000 description 8
- 210000003954 umbilical cord Anatomy 0.000 description 8
- 230000012292 cell migration Effects 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 7
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 230000006862 enzymatic digestion Effects 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003169 placental effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 210000001142 back Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000003837 chick embryo Anatomy 0.000 description 3
- 238000009795 derivation Methods 0.000 description 3
- 230000008556 epithelial cell proliferation Effects 0.000 description 3
- 208000000283 familial pityriasis rubra pilaris Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000003797 telogen phase Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000012432 Collagen Type V Human genes 0.000 description 2
- 108010022514 Collagen Type V Proteins 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000010208 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 description 2
- 108050001894 Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000010393 epithelial cell migration Effects 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000033687 granuloma formation Effects 0.000 description 2
- 230000009583 hair follicle growth Effects 0.000 description 2
- 230000003661 hair follicle regeneration Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 102000049853 macrophage stimulating protein Human genes 0.000 description 2
- 108010053292 macrophage stimulating protein Proteins 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000004202 respiratory function Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 102300058172 72 kDa type IV collagenase isoform 1 Human genes 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 108010043026 HGF activator Proteins 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 102100031465 Hepatocyte growth factor activator Human genes 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 108091069047 Homo sapiens let-7i stem-loop Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102300049684 Insulin-like growth factor II isoform 1 Human genes 0.000 description 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 1
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 1
- 102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 1
- 108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 description 1
- 102300047388 Insulin-like growth factor-binding protein 7 isoform 2 Human genes 0.000 description 1
- 102300046189 Insulin-like growth factor-binding protein complex acid labile subunit isoform 1 Human genes 0.000 description 1
- 101710107661 Interleukin enhancer-binding factor 2 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 102000049951 Nuclear Factor 45 Human genes 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 101710087172 Procollagen C-endopeptidase enhancer 1 Proteins 0.000 description 1
- 102100041026 Procollagen C-endopeptidase enhancer 1 Human genes 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 150000001455 metallic ions Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 231100000121 skin sensitizing Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0031—Serum-free culture media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/65—MicroRNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
- C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1388—Mesenchymal stem cells from other natural sources
Definitions
- the present invention relates to the field of stem cells and regenerative medicine.
- the present invention provides secretome derived from human placental Mesenchymal Stromal Cells.
- the benefits of clinical translation of secretome as a regenerative therapy is also provided.
- a cell-free conditioned cell culture medium comprising: (a) at least a protein selected from the group consisting of collagen alpha-1
- a method of preparing a conditioned cell culture medium comprising: (a) obtaining an enriched population of Mesenchymal Stromal Cells (MSCs); (b) seeding and culturing said enriched population of MSCs; and (c) collecting the cell culture medium, wherein step (a) comprises: (i) contacting at least a tissue with media comprising collagenase type 1 and collagenase type 2, wherein collagenase 1 weight concentration in said media is in the range of 0.04-0.1% and collagenase 2 weight concentration in said media is in the range of 0.04-0.1%; and (ii) isolating enriched fraction of MSCs.
- MSCs Mesenchymal Stromal Cells
- a cell-free conditioned cell culture medium obtained by a method of preparing a conditioned cell culture medium, the method comprising: (a) obtaining an enriched population of Mesenchymal Stromal Cells (MSCs);
- step (b) seeding and culturing said enriched population of MSCs; and (c) collecting the cell culture medium, wherein step (a) comprises: (i) contacting at least a tissue with media comprising collagenase type 1 and collagenase type 2, wherein collagenase 1 weight concentration in said media is in the range of 0.04-0.1% and collagenase 2 weight concentration in said media is in the range of 0.04-0.1%; and (ii) isolating enriched fraction of MSCs.
- a use of cell-free conditioned cell culture medium for use in tissue regeneration, vasculogenesis/angiogenesis, extra cellular matrix regeneration, or hair regeneration said cell culture medium obtained by a method of preparing a conditioned cell culture medium, the method comprising: (a) obtaining an enriched population of Mesenchymal Stromal Cells (MSCs); (b) seeding and culturing said enriched population of MSCs; and (c) collecting the cell culture medium, wherein step (a) comprises: (i) contacting at least a tissue with media comprising collagenase type 1 and collagenase type 2, wherein collagenase 1 weight concentration in said media is in the range of 0.04-0.1% and collagenase 2 weight concentration in said media is in the range of 0.04-0.1%; and (ii) isolating enriched fraction of MSCs.
- MSCs Mesenchymal Stromal Cells
- Fig.l depicts the results in in-vitro cell migration assay treatment regimen with percent cell migration, in accordance with an embodiment of the present invention.
- Fig. 2 depicts the pictorial representation of cell migration of different groups, in accordance with an embodiment of the present invention.
- Fig .3 depicts the graphical representation of neovascularization in chorio allantoic membrane assay, in accordance with an embodiment of the present invention.
- Fig. 4 depicts the pictorial representation of chorio allantoic membrane neovascularization under various test conditions, in accordance with an embodiment of the present invention.
- Fig. 5 depicts the graphical representation of animal weight in complete skin excisional wound mice model in different treatment groups, in accordance with an embodiment of the present invention.
- Fig. 6 depicts the H&E stain of wound area in complete skin excisional wound mice model in different treatment groups, in accordance with an embodiment of the present invention.
- Fig. 7 depicts the depicts the Masson Trichome stain of wound area in complete skin excisional wound mice model in different treatment groups, in accordance with an embodiment of the present invention
- Fig. 8 depicts the depicts the Mallory stain of wound area in complete skin excisional wound mice model in different treatment groups, in accordance with an embodiment of the present invention
- the present invention provides a cell-free conditioned cell culture medium comprising: (a) at least a protein selected from the group consisting of collagen alpha-1 (I), collagen alpha-2, type
- the fold change in collagen alpha-1 in serum starved cell culture medium is about 93-fold more than in serum free plain medium.
- the fold change in collagen apha-2 is serum starved cell culture medium is about 61-fold more than in serum free plain medium.
- the fold change in type IV collagenase isoform 2 is about 19- fold more than in serum free plain medium.
- the fold change in transforming growth factor beta induced protein ig-h3 is about 12-fold more than in serum free plain medium.
- the cell-free conditioned cell culture medium further comprises at least one or more of insulin like growth factor binding protein 7 isoform 2, 72kDa type IV collagenase isoform 1, interstitial collagenase isoform 2, collagen alpha 1(VI) chain isoform 2C2, insulin like growth factor II isoform 1, procollagen C endopeptidase enhancer 1, collagen alpha 2(V) chain, collagen alpha 2(1 V) chain, collagen alpha l(XII) chain long isoform, insulin like growth factor binding protein 4, collagen alpha 1(IV) chain isoform 1, insulin like growth factor binding protein complex acid labile subunit isoform 1, collagen alpha 2(V) chain isoform 1.
- the at least one or more protein is up-regulated by about 1.5-10-fold more than in serum fed cell culture medium.
- the cell-free conditioned cell culture medium further comprises at least one or more of insulin like growth factor binding protein 3 isoform b, hepatocyte growth factor like protein isoform 3, insulin like growth factor beta binding protein 2, collagen alpha 5(1 V) chain isoform 1, hepatocyte growth factor activator isoform 1, interleukin enhancer binding factor 2 isoform, insulin like growth factor binding protein 5, and hepatocyte growth factor like protein isoform 2.
- the at least one or more protein is down-regulated by about at least 1.1-fold less than in serum fed cell culture medium.
- the cell-free conditioned cell culture medium comprises hsa-miR-21-5p, hsa- miR-3191-3p, hsa-miR-100-5p, hsa-miR-let-7i-5p, hsa-miR-4682-3p.
- hsa-miR- 21-5p, hsa-miR-3191-3p, hsa-miR-100-5p, hsa-miR-let-7i-5p, and hsa-miR-4682-3p comprised in the cell-free conditioned cell culture medium are the top 5 represented miRNA species in the medium.
- the fold change in hsa-miR-21-5p miRNA in serum starved cell culture medium is about 1.8-fold less than in serum fed cell culture medium. In an embodiment, the fold change in hsa-miR-3191-3p miRNA in serum starved cell culture medium is about 1.65-fold less than in serum fed cell culture medium. In an embodiment, the fold change in hsa-miR-100-5p miRNA in serum starved cell culture medium is about 2.1-fold less than in serum fed cell culture medium. In an embodiment, the fold change in hsa-let-7i-5p miRNA in serum starved cell culture medium is about 3.6-fold less than in serum fed cell culture medium.
- the fold change in hsa-miR-4682-3p miRNA in serum starved cell culture medium is about 2.7-fold less than in serum fed cell culture medium.
- the medium is obtained from a mesenchymal stromal cell (MSC) culture.
- MSCs are derived from tissue selected from the group consisting of adipose tissue, dental pulp, mobilized peripheral blood, birth derived tissue, and placenta tissue. In a preferred embodiment, the tissue is placenta tissue.
- the medium is obtained is serum starved for 12-20 hours prior to collection. In a preferred embodiment, the media is serum starved for about 16 hours.
- the present invention also provides a method of preparing a conditioned cell culture medium, the method comprising: (i) obtaining an enriched population of Mesenchymal Stromal Cells (MSCs); (ii) seeding and culturing said enriched population of MSCs; and (iii) collecting the cell culture medium, wherein step (a) comprises: (a) contacting at least a tissue with media comprising collagenase type 1 and collagenase type 2, wherein collagenase 1 weight concentration in said media is in the range of 0.04-0.1% and collagenase 2 weight concentration in said media is in the range of 0.04-0.1%; and (b) isolating enriched fraction of MSCs.
- MSCs Mesenchymal Stromal Cells
- said tissue is selected from the group consisting of adipose tissue, dental pulp tissue, mobilized peripheral blood, birth derived tissue, and placenta tissue.
- the tissue is placenta tissue.
- step (i) is carried out for 20-40 minutes at 33-39°C, preferably 37°C.
- step (i) is devoid of trypsin.
- MSC confluence is 70-80% by day 20-25 at passage 0.
- the MSC purity in the MSC culture of step (ii) is in the range of 90-99%, preferably 98% at passage 3.
- the MSC are passaged for up to at least 15 times.
- the conditioned cell culture medium is collected from serum starved media, wherein the media is starved of serum for at least 12-20 hours. In a preferred embodiment, the media is serum starved for 16 hours.
- the present invention also provides a cell-free conditioned cell culture medium obtained by a process as substantially as described herein.
- the cell-free conditioned medium is for use in any one or more of tissue regeneration, vasculogenesis/angiogenesis, extra cellular matrix regeneration, or hair regeneration.
- the secretome comprised in the cell free serum starved growth medium converts telogen phase to anagen phase in hair follicle growth cycle; decreases factors like BMP2/4, which are responsible for refractory phase in telogen, thereby converting refractory phase to competent phase in telogen, which induct anagen phase through stem cell activation in the local milieu; activation of signaling pathways like Wnt/ -catenin, which is responsible for anagen induction; regulation of hair follicle growth cycle; activation of resident stem cell milieu by the paracrine molecular signaling for initiation of anagen phase of hair cycle; proteoglycans in the secretome act as natural fillers for stable ECM formation in between aging cells; secretome is rich in angiogenic factors for improving skin vascularity; fibroblast activation leads to fresh collagen deposition for firmer skin.
- a splinted skin excisional wound mice model was made by an impression of diameter 1-cm on depilated dorsum at two regions 1cm apart from each other and thereby the wound is created by using toothed forceps and pointed scissors. The area under the impression is cut with full thickness and injected with the media of the present invention to evaluate skin regeneration, including epidermis, dermis and dermal papilla and hair regeneration.
- Fetal Bovine Serum The animal component, Fetal Bovine Serum (FBS) is replaced with human umbilical cord fetal serum, which is a newly defined medium described previously (Vibudha Nanduri et.al, Reconstruction of Hyaline Cartilage Deep Layer Properties in 3-Dimensional Cultures of Human Articular Chondrocytes. Orthop J Sports Med. 2014 Jun; 2(6): 2325967114539122).
- Trypsin is used routinely for isolation of MSCs from placenta. In previous study using the explant method, it is suggested that degradation of the extracellular matrix and disintegration of cell membranes may cause cellular damage through the use of trypsin alone of a long period.
- the combination of collagenase type I and type II are used to digest the tissue, to the exclusion of trypsin, which results in unexpected and surprising better cell release. Enzymatic digestion by collagenase type I and II was found to be more efficient for cell isolation and culturing compared to other known methods described in the art for MSC derivation. Use of collagenase type I and II resulted in shorter time taken to reach 70-80% confluency compared to known methods.
- Placental tissue was digested with collagenase type I or collagenase type II individually with trypsin. In each case, it was observed that dissociation of tissue was slow. In contrast, the application of both collagenase type I and II unexpectedly and surprisingly, led to faster tissue dissociation.
- the placental MSCs derived by this method also reached 70-80% confluency in a shorter time period of 20-25 days at passage 0.
- UC umbilical cord
- collagenases The enzymatic degradation by collagenases is essential for cell derivation process as described previously to maximize cell yield.
- EDTA Ethylenediaminetetraacetic acid
- EGTA ethylene glycol-bis( -aminoethyl ether)-N,N,N',N'- tetra acetic acid
- a2-macroglobulin Cysteine
- Cysteine histidine
- DTT Dithiothreitol
- 2-mercaptoethanol 2-mercaptoethanol
- O-phenanthroline metallic ions such as Hg 2+ , Pb 2+ , Cd 2+ , Cu 2+ .
- human UC serum has a2- macroglobulin as a major component, which can inhibit enzyme activity of collagenases to prevent cellular damage.
- Advantageously human UC serum can be used for xeno-free cell culture method for safe use in therapeutic applications.
- growth factor enriched serum also makes it an efficient supplement for cells.
- tissue is cut into small fragments followed by mincing in a stirrer liquidizer for 15-25 seconds (10000RPM) followed by enzymatic digestion for 30-45 minutes at 37°C.
- the enzymatic digestion is done with collagenase type I (60mg) and type II (60mg) reconstituted in 30ml PBS.
- the enzymatic reaction is neutralized with 10% human umbilical cord serum with
- DMEM fetal calf serum
- T75 vented flasks The medium is changed every 3-4 days until the cells reach confluency of about 70-80% in about 5-7 days, post which, the supernatant is collected (supernatant collected is post serum starvation). The supernatant collected is centrifuged at 500g for 10 minutes and filtered using
- the cells were first seeded onto a 6 well plate. The cells were incubated until they reached full confluence (>95%). Using a sterile lOul tip, a scratch was introduced onto each well of 6 well plate. The wells were washed thrice with plain medium and incubated in presence of supernatant with different concentrations mixed with media. The cells were incubated for 24h at 37°C in CO2 incubator. After the treatment, the cells were washed twice with Dulbecco's Phosphate Buffered Saline and the images were taken in inverted microscope. The scratch distance before and after the treatment was recorded as using image J software and the graph was plotted. The experiment was done in triplicate and the statistical significance (one way ANOVA) was calculated.
- Figure 1 depicts the graphical representation of wound healing assay using escalating doses of secretome and compared with control (untreated group)
- escalating doses of secretome clearly inhibits cell migration in tumor cells (Hela cell line) which gives a direction into therapeutic dose determination in regenerative medicine in preventing tumorigenicity.
- Fig. 3 depicts the histogram representing the neovascularization effect of secretome in the in- ovo CAM assay
- the secretome appeared to improve wound healing at low concentrations when compared to untreated cells.
- the secretome appeared to have angiogenic effect on the chorio allantoic membrane of chick embryo, which can be observed from the number of capillaries and their branching. These effects are mediated by their incorporation into newly formed blood vessels or paracrine secretion of proangiogenic factors that stimulate the host chicken endothelial cells.
- the angiogenic effects of secretome were comparable with the positive control i.e., Hela cells.
- chorio allantoic Membrane to test the angiogenesis. 5 treatments to test the angiogenic potential of the secretome. a) placebo, b) secretome, c) HeLa (positive control), d) Hela + SeNP and e) secretome+ SeNP (Selenium nanoparticle: negative control) were performed
- mice Three Male Balb C mice around 10 weeks weighing about 25-30 grams was used in Primary Irritation Test. Animals were restrained by holding the tail and applying depilatory cream on their back and the cream was wiped off with sterile cotton after 2 minutes. The area was then sterilized with 70% isopropanol. 2 patches (10 units in each patch; 1cm apart) of secretome derived from human placental MSCs was injected subcutaneously to all the mice and observed after 5 min, 15 min, 30 min and 60 minutes and after 24 hours, 48 hours and 72 hours. Observations for skin inflammation, erythema at the site of injection were performed at least once in a day for 3 days.
- mice of male sex were grouped into Group-1 (PBS) containing 6 mice, Group-2 (Secretome) containing 14 mice and Group-3 (PRP) containing 6 mice.
- PBS Group-1
- Group-2 Stressome
- PRP Group-3
- Animals were under pellet feeding and provided with ad libitum water throughout experiment. Animals were housed in cages following caging standards of mice, each animal per one cage. Animals were handled under care throughout the experiment and humane practices followed for euthanizing the animals. Animals euthanized with high dosage of anesthesia intraperitoneally.
- the silicone splint of diameter 10mm placed on the excised wounds and sutured at three points on wound to keep the splints intact. Each animal was caged separately and observed for 14 days. Daily imaging of the animals, wound re-epithelialization and contraction was observed, weights of animals was recorded on all days. Digital quantification of wound was evaluated on day 0, day 1, day 7, day 10 and dayl4.
- Fig. 5 depicts the graphical representation of animal weights in complete skin excisional would mice model in different treatment groups. Changes in body weight of animals in different treatment groups. The animals in different treatment groups gained weight throughout the period of study. However, there is a decline in the animal weights in PBS, PRP group when compared with secretome group.
- Fig. 6 depicts the H&E stain images.
- FIG. 6A shows PBS group Day 10; minimal cell proliferation, granuloma formation and fibrosis is evidenced, irregular epithelialization, disorientation of collagen matrix is observed;
- Fig. 6B shows PBS group Day- 14; Thick layer of epithelialization, collagen formation is decreased comparatively with the day 10, increased granulation;
- Fig. 6C shows hMSC-Secretome group Day-10; Systematic collagen organization & cellular proliferation & migration is noticed;
- Fig. 6D shows hMSC-Secretome group Day-10; Neovascularization is observed;
- Fig. 6E shows hMSC-secretome group day-14; new collagen deposition in the newly formed ECM noted;
- FIG. 6F shows PRP group Day-10; Scab formation is seen, disorientation of the Extracellular matrix, vascularization is noticed;
- Fig. 6G shows PRP group Day-14; cellular proliferation becoming less compared to day 10, no ECM deposition no cell migration is seen supporting EMT (Epithelial Mesenchymal Transition), complete absence of de novo regeneration of hair follicle.
- H & E staining of skin tissues demonstrates inflammatory cells infiltration and found to be low in secretome group when compared with PRP group (positive control) and PBS group (untreated, negative control).
- the severe inflammatory cell infiltration, very minimal epithelial cell proliferation and granuloma formation was observed in PBS group.
- PRP group there was mild inflammatory cell infiltration along with epithelial cell proliferation (on day 10 but decreased by day 14) with no epithelial cell migration to support EMT.
- secretome group we have observed very mild inflammatory cell infiltration, epithelial cell proliferation and migration (Epithelial- Mesenchymal Transition). There is a complete restoration of all the layers of the skin epidermis and the dermis.
- the activation of EMT is clearly noted in the H & E with the epidermal cells migrating into the dermis and also activating the mesenchyme to form the dermal papilla.
- Fig. 7 depicts Masson Trichome stain images.
- Fig. 7A shows PBS group Day 10; No cellular differentiation, absence of dermal papilla, severe fibrosis and migration of fibrous tissue;
- Fig. 7B shows PBS group Day- 14; No de novo hair follicles seen, vascularization not noticed;
- Fig. 7C shows hMSC-Secretome group Day-10; Cell proliferation & migration with the deposition of new collagen in the ECM;
- Fig. 7D shows hMSC-secretome group day-14; Structural remodeling of the full thickness skin with new collagen deposition;
- Fig. 7E shows hMSC-secretome group day-14; De novo Dermal papilla regeneration with complete skin modelling;
- Fig. 7F shows PRP group Day- 10; Partial re-epithelialization, severe fibrosis migration of fibrosis;
- Fig. 7G shows PRP group Day-
- Fig. 7H shows PRP group Day-14; No cellular migration and proliferation, instead noticed extension of the fibrosis into the deeper layers.
- Masson trichome stain is a marker to assess granuloma and extracellular matrix formation analyzed through collagen fiber deposition.
- secretome group we have found in secretome group, that the collagen deposition and their orientation in ECM was not deviated from the normal skin indicating that the collagen deposition due to secretome would not results in fibrotic scar formation.
- Fig. 8 shows Mallory stain images for hMSC secretome group.
- Fig. 8A shows hMSC secretome group day-10; Complete Epidermal regeneration and migration (EMT) into the dermis with a de novo hair follicle regeneration;
- Fig. 8B shows hMSC secretome group day-10; Complete re- epithelialization, neovascularization noticed;
- Fig. 8C shows hMSC Secretome group day- 14; De novo hair follicle regeneration is seen, collagen formation is noticed;
- Fig. 8D shows hMSC Secretome group day-14; Neovascularization is noticed;
- Fig. 8E shows hMSC Secretome group day-14; Keratin formation, epidermal proliferation and epidermal cell migration into the dermis
- the present invention provides a cell-free conditioned MSC culture medium, which has unique functionality in skin and hair regeneration. Also, particularly, a novel and inventive method of MSC culturing is provided which is superior than known methods in the art.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a GMP compliant, scalable process of a cell-free, xeno-free protein and miRNA rich product derived from human placenta i.e., Mesenchymal stromal cell secretome useful for intradermal/subcutaneous administration for hair regeneration and skin rejuvenation. Also provided is a product obtainable from the process and uses thereof.
Description
PLACENTA DERIVED MESENCHYMAL STROMAL CELL SECRETOME, PROCESS AND USES
THEREOF
FIELD OF INVENTION
The present invention relates to the field of stem cells and regenerative medicine. In particular, the present invention provides secretome derived from human placental Mesenchymal Stromal Cells. The benefits of clinical translation of secretome as a regenerative therapy is also provided.
BACKGROUND OF THE PRESENT INVENTION
Conventional management for skin rejuvenation and hair loss are limited to chemical agents such as finasteride and minoxidil and allogenic platelet rich plasma. However, the side effects due to long-term usage of minoxidil and difficulties in repetitive administration in PRP therapy have restricted the above as standard and approved therapies. There is an unmet need of safe, non toxic proteome derived to suit clinical or cosmeceutical application.
SUMMARY OF THE PRESENT INVENTION
In an aspect of the present invention, there is provided a cell-free conditioned cell culture medium comprising: (a) at least a protein selected from the group consisting of collagen alpha-1
(I), collagen alpha-2, type IV collagenase isoform 2, collagen alpha-1 (III), transforming growth factor-beta induced protein ig-hB, and combinations thereof; and (b) at least a mi-RNA selected from the group consisting of hsa-miR-21-5p, hsa-miR-3191-3p, hsa-miR-100-5p, hsa-miR-let-7i- 5p, hsa-miR-4682-3p, and combinations thereof, wherein, the medium is serum starved cell culture medium, wherein the fold change in at least a protein is 10-95-fold more than in serum free plain media and fold change in at least a mi-RNA is 1.5-4-fold less than in serum fed culture media.
In another aspect of the present invention, there is provided a method of preparing a conditioned cell culture medium, the method comprising: (a) obtaining an enriched population of Mesenchymal Stromal Cells (MSCs); (b) seeding and culturing said enriched population of MSCs; and (c) collecting the cell culture medium, wherein step (a) comprises: (i) contacting at least a tissue with media comprising collagenase type 1 and collagenase type 2, wherein collagenase 1 weight concentration in said media is in the range of 0.04-0.1% and collagenase 2 weight
concentration in said media is in the range of 0.04-0.1%; and (ii) isolating enriched fraction of MSCs.
In yet another aspect of the present invention, there is provided a cell-free conditioned cell culture medium obtained by a method of preparing a conditioned cell culture medium, the method comprising: (a) obtaining an enriched population of Mesenchymal Stromal Cells (MSCs);
(b) seeding and culturing said enriched population of MSCs; and (c) collecting the cell culture medium, wherein step (a) comprises: (i) contacting at least a tissue with media comprising collagenase type 1 and collagenase type 2, wherein collagenase 1 weight concentration in said media is in the range of 0.04-0.1% and collagenase 2 weight concentration in said media is in the range of 0.04-0.1%; and (ii) isolating enriched fraction of MSCs.
In still another aspect of the present invention, there is provided a use of cell-free conditioned cell culture medium for use in tissue regeneration, vasculogenesis/angiogenesis, extra cellular matrix regeneration, or hair regeneration, said cell culture medium obtained by a method of preparing a conditioned cell culture medium, the method comprising: (a) obtaining an enriched population of Mesenchymal Stromal Cells (MSCs); (b) seeding and culturing said enriched population of MSCs; and (c) collecting the cell culture medium, wherein step (a) comprises: (i) contacting at least a tissue with media comprising collagenase type 1 and collagenase type 2, wherein collagenase 1 weight concentration in said media is in the range of 0.04-0.1% and collagenase 2 weight concentration in said media is in the range of 0.04-0.1%; and (ii) isolating enriched fraction of MSCs.
BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS
Fig.l depicts the results in in-vitro cell migration assay treatment regimen with percent cell migration, in accordance with an embodiment of the present invention.
Fig. 2 depicts the pictorial representation of cell migration of different groups, in accordance with an embodiment of the present invention.
Fig .3 depicts the graphical representation of neovascularization in chorio allantoic membrane assay, in accordance with an embodiment of the present invention.
Fig. 4 depicts the pictorial representation of chorio allantoic membrane neovascularization under various test conditions, in accordance with an embodiment of the present invention.
Fig. 5 depicts the graphical representation of animal weight in complete skin excisional wound mice model in different treatment groups, in accordance with an embodiment of the present invention.
Fig. 6 depicts the H&E stain of wound area in complete skin excisional wound mice model in different treatment groups, in accordance with an embodiment of the present invention.
Fig. 7 depicts the depicts the Masson Trichome stain of wound area in complete skin excisional wound mice model in different treatment groups, in accordance with an embodiment of the present invention
Fig. 8 depicts the depicts the Mallory stain of wound area in complete skin excisional wound mice model in different treatment groups, in accordance with an embodiment of the present invention
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a cell-free conditioned cell culture medium comprising: (a) at least a protein selected from the group consisting of collagen alpha-1 (I), collagen alpha-2, type
IV collagenase isoform 2, collagen alpha-l(lll), transforming growth factor-beta induced protein ig-h3, and combinations thereof; and (b) at least a mi-RNA selected from the group consisting of hsa-miR-21-5p, hsa-miR-3191-3p, hsa-miR-100-5p, hsa-miR-let-7i-5p, hsa-miR-4682-3p, and combinations thereof, wherein, the medium is serum starved cell culture medium, wherein the fold change in at least a protein is 10-95-fold more than in serum free plain medium and fold change in at least a mi-RNA is 1.5-3-fold less than in serum fed cell culture medium.
In an embodiment, the fold change in collagen alpha-1 in serum starved cell culture medium is about 93-fold more than in serum free plain medium. In another embodiment, the fold change in collagen apha-2 is serum starved cell culture medium is about 61-fold more than in serum free plain medium. In an embodiment, the fold change in type IV collagenase isoform 2 is about 19- fold more than in serum free plain medium. In another embodiment, the fold change in transforming growth factor beta induced protein ig-h3 is about 12-fold more than in serum free plain medium.
In an embodiment, the cell-free conditioned cell culture medium further comprises at least one or more of insulin like growth factor binding protein 7 isoform 2, 72kDa type IV collagenase isoform 1, interstitial collagenase isoform 2, collagen alpha 1(VI) chain isoform 2C2, insulin like growth factor II isoform 1, procollagen C endopeptidase enhancer 1, collagen alpha 2(V) chain, collagen alpha 2(1 V) chain, collagen alpha l(XII) chain long isoform, insulin like growth factor binding protein 4, collagen alpha 1(IV) chain isoform 1, insulin like growth factor binding protein complex acid labile subunit isoform 1, collagen alpha 2(V) chain isoform 1. In an embodiment, the at least one or more protein is up-regulated by about 1.5-10-fold more than in serum fed cell culture medium.
In an embodiment, the cell-free conditioned cell culture medium further comprises at least one or more of insulin like growth factor binding protein 3 isoform b, hepatocyte growth factor like protein isoform 3, insulin like growth factor beta binding protein 2, collagen alpha 5(1 V) chain isoform 1, hepatocyte growth factor activator isoform 1, interleukin enhancer binding factor 2 isoform, insulin like growth factor binding protein 5, and hepatocyte growth factor like protein isoform 2. In an embodiment, the at least one or more protein is down-regulated by about at least 1.1-fold less than in serum fed cell culture medium.
In an embodiment, the cell-free conditioned cell culture medium comprises hsa-miR-21-5p, hsa- miR-3191-3p, hsa-miR-100-5p, hsa-miR-let-7i-5p, hsa-miR-4682-3p. In an embodiment, hsa-miR- 21-5p, hsa-miR-3191-3p, hsa-miR-100-5p, hsa-miR-let-7i-5p, and hsa-miR-4682-3p comprised in the cell-free conditioned cell culture medium are the top 5 represented miRNA species in the medium.
In an embodiment, the fold change in hsa-miR-21-5p miRNA in serum starved cell culture medium is about 1.8-fold less than in serum fed cell culture medium. In an embodiment, the fold change in hsa-miR-3191-3p miRNA in serum starved cell culture medium is about 1.65-fold less than in serum fed cell culture medium. In an embodiment, the fold change in hsa-miR-100-5p miRNA in serum starved cell culture medium is about 2.1-fold less than in serum fed cell culture medium. In an embodiment, the fold change in hsa-let-7i-5p miRNA in serum starved cell culture medium is about 3.6-fold less than in serum fed cell culture medium. In an embodiment, the fold change in hsa-miR-4682-3p miRNA in serum starved cell culture medium is about 2.7-fold less than in serum fed cell culture medium.
In an embodiment, the medium is obtained from a mesenchymal stromal cell (MSC) culture. The MSCs are derived from tissue selected from the group consisting of adipose tissue, dental pulp, mobilized peripheral blood, birth derived tissue, and placenta tissue. In a preferred embodiment, the tissue is placenta tissue.
In an embodiment, the medium is obtained is serum starved for 12-20 hours prior to collection. In a preferred embodiment, the media is serum starved for about 16 hours.
The present invention also provides a method of preparing a conditioned cell culture medium, the method comprising: (i) obtaining an enriched population of Mesenchymal Stromal Cells (MSCs); (ii) seeding and culturing said enriched population of MSCs; and (iii) collecting the cell culture medium, wherein step (a) comprises: (a) contacting at least a tissue with media comprising collagenase type 1 and collagenase type 2, wherein collagenase 1 weight concentration in said media is in the range of 0.04-0.1% and collagenase 2 weight concentration in said media is in the range of 0.04-0.1%; and (b) isolating enriched fraction of MSCs.
In an embodiment, said tissue is selected from the group consisting of adipose tissue, dental pulp tissue, mobilized peripheral blood, birth derived tissue, and placenta tissue. In a preferred embodiment, the tissue is placenta tissue.
In an embodiment, step (i) is carried out for 20-40 minutes at 33-39°C, preferably 37°C. In a preferred embodiment, step (i) is devoid of trypsin. In an embodiment, in step (ii) after seeding, MSC confluence is 70-80% by day 20-25 at passage 0. In an embodiment, the MSC purity in the MSC culture of step (ii) is in the range of 90-99%, preferably 98% at passage 3. In an embodiment, in step (ii) the MSC are passaged for up to at least 15 times. In an embodiment, the conditioned cell culture medium is collected from serum starved media, wherein the media is starved of serum for at least 12-20 hours. In a preferred embodiment, the media is serum starved for 16 hours.
The present invention also provides a cell-free conditioned cell culture medium obtained by a process as substantially as described herein. The cell-free conditioned medium is for use in any one or more of tissue regeneration, vasculogenesis/angiogenesis, extra cellular matrix regeneration, or hair regeneration.
EXAMPLES
Example 1
Comparison of existing cosmeceutical therapies with the cell-free conditioned cell culture medium of the present invention
Example 2
Advantages of the medium of the present invention
The secretome comprised in the cell free serum starved growth medium converts telogen phase to anagen phase in hair follicle growth cycle; decreases factors like BMP2/4, which are
responsible for refractory phase in telogen, thereby converting refractory phase to competent phase in telogen, which induct anagen phase through stem cell activation in the local milieu; activation of signaling pathways like Wnt/ -catenin, which is responsible for anagen induction; regulation of hair follicle growth cycle; activation of resident stem cell milieu by the paracrine molecular signaling for initiation of anagen phase of hair cycle; proteoglycans in the secretome act as natural fillers for stable ECM formation in between aging cells; secretome is rich in angiogenic factors for improving skin vascularity; fibroblast activation leads to fresh collagen deposition for firmer skin.
Example 3
Establishing proof of concept study using animal model with a complete excisional skin wound
A splinted skin excisional wound mice model was made by an impression of diameter 1-cm on depilated dorsum at two regions 1cm apart from each other and thereby the wound is created by using toothed forceps and pointed scissors. The area under the impression is cut with full thickness and injected with the media of the present invention to evaluate skin regeneration, including epidermis, dermis and dermal papilla and hair regeneration.
Example 4
Cell-free xeno-free human placenta derived conditioned medium
The animal component, Fetal Bovine Serum (FBS) is replaced with human umbilical cord fetal serum, which is a newly defined medium described previously (Vibudha Nanduri et.al, Reconstruction of Hyaline Cartilage Deep Layer Properties in 3-Dimensional Cultures of Human Articular Chondrocytes. Orthop J Sports Med. 2014 Jun; 2(6): 2325967114539122).
Example 5
Choice of enzymes for tissue digestion
Trypsin is used routinely for isolation of MSCs from placenta. In previous study using the explant method, it is suggested that degradation of the extracellular matrix and disintegration of cell membranes may cause cellular damage through the use of trypsin alone of a long period.
In the present case, the combination of collagenase type I and type II are used to digest the tissue, to the exclusion of trypsin, which results in unexpected and surprising better cell release. Enzymatic digestion by collagenase type I and II was found to be more efficient for cell isolation and culturing compared to other known methods described in the art for MSC derivation. Use of collagenase type I and II resulted in shorter time taken to reach 70-80% confluency compared to known methods. Compared to implant technique, using the present process, less contamination and faster growth of cells were seen in the present cell suspension method. Collagenase type I and type II mediated enzymatic digestion of tissue had better efficiency of cell release that trypsin and collagenase type I or trypsin and collagenase type II. Cells were 90% confluent after 9-12 days compared to 14-18 days in conventional methods.
Example 6
Synergistic effect of collagenase type I and type II in placental MSC isolation and expansion
Placental tissue was digested with collagenase type I or collagenase type II individually with trypsin. In each case, it was observed that dissociation of tissue was slow. In contrast, the application of both collagenase type I and II unexpectedly and surprisingly, led to faster tissue dissociation. The placental MSCs derived by this method also reached 70-80% confluency in a shorter time period of 20-25 days at passage 0.
Example 7
Use of human umbilical cord (UC) serum for xeno free cell culture conditions and as inhibitor of collagenase
The enzymatic degradation by collagenases is essential for cell derivation process as described previously to maximize cell yield. There are several inhibitors of collagenases such as EDTA (Ethylenediaminetetraacetic acid), EGTA (ethylene glycol-bis( -aminoethyl ether)-N,N,N',N'- tetra acetic acid),a2-macroglobulin, Cysteine, histidine, DTT (Dithiothreitol), 2-mercaptoethanol, O-phenanthroline, metallic ions such as Hg2+, Pb2+, Cd2+, Cu2+. However, human UC serum has a2- macroglobulin as a major component, which can inhibit enzyme activity of collagenases to prevent cellular damage. Advantageously human UC serum can be used for xeno-free cell culture
method for safe use in therapeutic applications. Further, growth factor enriched serum also makes it an efficient supplement for cells.
Example 8
Cell derivation process and media collection Placenta, umbilical cord and amniotic membrane are collected after LSCS, washed with saline for
10-15 minutes to remove blood and then suspended in lx PBS until the tissue become pale pink in colour. Next, the tissue is cut into small fragments followed by mincing in a stirrer liquidizer for 15-25 seconds (10000RPM) followed by enzymatic digestion for 30-45 minutes at 37°C. The enzymatic digestion is done with collagenase type I (60mg) and type II (60mg) reconstituted in 30ml PBS. The enzymatic reaction is neutralized with 10% human umbilical cord serum with
DMEM and filtered using 250-micron sieve. It is then centrifuged at 1500RPM for 20 minutes and the pellet is dissolved in DMEM with human umbilical cord serum and plated in T75 vented flasks. The medium is changed every 3-4 days until the cells reach confluency of about 70-80% in about 5-7 days, post which, the supernatant is collected (supernatant collected is post serum starvation). The supernatant collected is centrifuged at 500g for 10 minutes and filtered using
0.2-micron filter and stored for further use.
Example 9 in-vitro cell migration assay/wound healing assay
To determine the wound healing propensity of HeLa cancer cells in presence of the collected supernatant/media, the cells were first seeded onto a 6 well plate. The cells were incubated until they reached full confluence (>95%). Using a sterile lOul tip, a scratch was introduced onto each well of 6 well plate. The wells were washed thrice with plain medium and incubated in presence of supernatant with different concentrations mixed with media. The cells were incubated for 24h at 37°C in CO2 incubator. After the treatment, the cells were washed twice with Dulbecco's Phosphate Buffered Saline and the images were taken in inverted microscope. The scratch distance before and after the treatment was recorded as using image J software and the graph was plotted. The experiment was done in triplicate and the statistical significance (one way ANOVA) was calculated.
Figure 1 depicts the graphical representation of wound healing assay using escalating doses of secretome and compared with control (untreated group)
As seen in Fig. 2 escalating doses of secretome clearly inhibits cell migration in tumor cells (Hela cell line) which gives a direction into therapeutic dose determination in regenerative medicine in preventing tumorigenicity.
At higher doses of secretome, inhibition of migration of cancer cells (Hela cells) is observed, which indicates that the media derived from a fetal tissue exhibits a balance between canonical Wnt signaling and sonic hedgehog pathway thereby balancing over expression of Wnt signaling pathway which prevents migration and proliferation of abnormal cells. Example 10
A comparative study of chick embryo chorio allantoic membrane assay to check the neovascularization following hMSC derived secretome injection:
Fertilized 8 days old chick embryos were incubated at 37° C under 85% humidity. 11-day old egg were used for the experiment. The eggs were sterilized using surgical spirit and the blood vessels was marked using the Egg Candler 1 day prior to inoculation. A hole was made carefully using a sterile needle along the side of the egg. 200mI of supernatant was inoculated and sealed. 106 cells were inoculated onto the CAM layer through this hole as a positive control and later sealed using wax. These cells were further inoculated for 3 days in the incubator. The cells were harvested by
break opening the egg shell and separating the CAM layer. The CAM layer was placed onto the petri dish and the neovascularization was quantified by counting the number of blood vessel branch points. A graph was plotted with treatment on x-axis and blood vessels formed on y-axis.
Fig. 3 depicts the histogram representing the neovascularization effect of secretome in the in- ovo CAM assay
Addition of the media/secretome of the present invention appeared to improve wound healing at low concentrations when compared to untreated cells. The secretome appeared to have angiogenic effect on the chorio allantoic membrane of chick embryo, which can be observed from the number of capillaries and their branching. These effects are mediated by their incorporation into newly formed blood vessels or paracrine secretion of proangiogenic factors that stimulate the host chicken endothelial cells. The angiogenic effects of secretome were comparable with the positive control i.e., Hela cells.
As seen in Fig. 4, chorio allantoic Membrane to test the angiogenesis. 5 treatments to test the angiogenic potential of the secretome. a) placebo, b) secretome, c) HeLa (positive control), d) Hela + SeNP and e) secretome+ SeNP (Selenium nanoparticle: negative control) were performed
Example 11
Toxicity study
Three Male Balb C mice around 10 weeks weighing about 25-30 grams was used in Primary Irritation Test. Animals were restrained by holding the tail and applying depilatory cream on their back and the cream was wiped off with sterile cotton after 2 minutes. The area was then sterilized with 70% isopropanol. 2 patches (10 units in each patch; 1cm apart) of secretome derived from human placental MSCs was injected subcutaneously to all the mice and observed after 5 min, 15 min, 30 min and 60 minutes and after 24 hours, 48 hours and 72 hours. Observations for skin inflammation, erythema at the site of injection were performed at least once in a day for 3 days. Also observed were skin sensitizing properties like changes in eye, skin, mucous membrane; respiratory functions, behavioural patterns, body weight, feed intake, water consumption. Special attention was paid at the site of injection.
No hypersensitivity reaction was observed in all the 3 mice, with no changes in body weight, feed intake and activity of the animal. No changes were observed at the site of injection. No significant behavioural patterns like seizures, convulsions were observed. No changes in respiratory functions were observed. Example 12
Animal study in regeneration of skin (epidermal, dermal, dermal papilla) and hair
A total of 26 (6+14+6) BALB-C strain mice of male sex (age 8 weeks, weight 25-35g) were grouped into Group-1 (PBS) containing 6 mice, Group-2 (Secretome) containing 14 mice and Group-3 (PRP) containing 6 mice. Animals were under pellet feeding and provided with ad libitum water throughout experiment. Animals were housed in cages following caging standards of mice, each animal per one cage. Animals were handled under care throughout the experiment and humane practices followed for euthanizing the animals. Animals euthanized with high dosage of anesthesia intraperitoneally.
Preparation of excision wound model in mice After anesthetization, about 0.25ml blood was collected from 3 animals randomly from retro- orbital sinus. Dorsum of the animal is depilated and rubbed with 70% ethyl alcohol. An excisional wound was made by an impression of diameter 10mm on depilated dorsum at two regions 1cm apart from each. Wound was created by using toothed forceps and pointed scissors the area under impression was cut with full thickness. After excision of wound, 100 microliters of PBS administered to Group 1 (control) animals, 100 microliters secretome administered for Group-2 and 100 microliters of PRP administered to group 3 (positive control), 50 microliters at each wound given at the center and around the wound at all clock positions subcutaneously. The silicone splint of diameter 10mm placed on the excised wounds and sutured at three points on wound to keep the splints intact. Each animal was caged separately and observed for 14 days. Daily imaging of the animals, wound re-epithelialization and contraction was observed, weights of animals was recorded on all days. Digital quantification of wound was evaluated on day 0, day 1, day 7, day 10 and dayl4.
On day 10, from each group of 3 animals, total 9 animals were sacrificed by high dosage of anesthesia. About 1ml blood was collected through retro-orbital sinus from each animal in EDTA
IB
coated tubes and clot activator for serum separation. The wound area was cut along with the normal skin from each wound and kept in 10% formalin. Further these tissues were used for H&E staining, collagen staining and for immunohistochemistry procedures. Same procedure was followed on day 14 to extract the tissue for staining and immunohistochemistry. Fig. 5 depicts the graphical representation of animal weights in complete skin excisional would mice model in different treatment groups. Changes in body weight of animals in different treatment groups. The animals in different treatment groups gained weight throughout the period of study. However, there is a decline in the animal weights in PBS, PRP group when compared with secretome group. Fig. 6 depicts the H&E stain images. Fig. 6A shows PBS group Day 10; minimal cell proliferation, granuloma formation and fibrosis is evidenced, irregular epithelialization, disorientation of collagen matrix is observed; Fig. 6B shows PBS group Day- 14; Thick layer of epithelialization, collagen formation is decreased comparatively with the day 10, increased granulation; Fig. 6C shows hMSC-Secretome group Day-10; Systematic collagen organization & cellular proliferation & migration is noticed; Fig. 6D shows hMSC-Secretome group Day-10; Neovascularization is observed; Fig. 6E shows hMSC-secretome group day-14; new collagen deposition in the newly formed ECM noted; Fig. 6F shows PRP group Day-10; Scab formation is seen, disorientation of the Extracellular matrix, vascularization is noticed; Fig. 6G shows PRP group Day-14; cellular proliferation becoming less compared to day 10, no ECM deposition no cell migration is seen supporting EMT (Epithelial Mesenchymal Transition), complete absence of de novo regeneration of hair follicle.
H & E staining of skin tissues demonstrates inflammatory cells infiltration and found to be low in secretome group when compared with PRP group (positive control) and PBS group (untreated, negative control). The severe inflammatory cell infiltration, very minimal epithelial cell proliferation and granuloma formation was observed in PBS group. In PRP group, there was mild inflammatory cell infiltration along with epithelial cell proliferation (on day 10 but decreased by day 14) with no epithelial cell migration to support EMT. In secretome group, we have observed very mild inflammatory cell infiltration, epithelial cell proliferation and migration (Epithelial- Mesenchymal Transition). There is a complete restoration of all the layers of the skin epidermis
and the dermis. The activation of EMT is clearly noted in the H & E with the epidermal cells migrating into the dermis and also activating the mesenchyme to form the dermal papilla.
Fig. 7 depicts Masson Trichome stain images. Fig. 7A shows PBS group Day 10; No cellular differentiation, absence of dermal papilla, severe fibrosis and migration of fibrous tissue; Fig. 7B shows PBS group Day- 14; No de novo hair follicles seen, vascularization not noticed; Fig. 7C shows hMSC-Secretome group Day-10; Cell proliferation & migration with the deposition of new collagen in the ECM; Fig. 7D shows hMSC-secretome group day-14; Structural remodeling of the full thickness skin with new collagen deposition; Fig. 7E shows hMSC-secretome group day-14; De novo Dermal papilla regeneration with complete skin modelling; Fig. 7Fshows PRP group Day- 10; Partial re-epithelialization, severe fibrosis migration of fibrosis; Fig. 7G shows PRP group Day-
14; Absence of hair follicles in the wounded area, decreased vascularization, decreased EMT; Fig. 7H shows PRP group Day-14; No cellular migration and proliferation, instead noticed extension of the fibrosis into the deeper layers.
Masson trichome stain is a marker to assess granuloma and extracellular matrix formation analyzed through collagen fiber deposition. In our experiment, we have found in secretome group, that the collagen deposition and their orientation in ECM was not deviated from the normal skin indicating that the collagen deposition due to secretome would not results in fibrotic scar formation.
Fig. 8 shows Mallory stain images for hMSC secretome group. Fig. 8A shows hMSC secretome group day-10; Complete Epidermal regeneration and migration (EMT) into the dermis with a de novo hair follicle regeneration; Fig. 8B shows hMSC secretome group day-10; Complete re- epithelialization, neovascularization noticed; Fig. 8C shows hMSC Secretome group day- 14; De novo hair follicle regeneration is seen, collagen formation is noticed; Fig. 8D shows hMSC Secretome group day-14; Neovascularization is noticed; Fig. 8E shows hMSC Secretome group day-14; Keratin formation, epidermal proliferation and epidermal cell migration into the dermis
(mesoderm) with the dermal papilla formation, sub-epidermal thin collagen deposition and structural remodeling of the entire skin and hair follicle.
Mallory stain of skin tissue will be applied in detecting the collagen and iron depositions (blood vessels). The secretome group demonstrated that there were collagen fibers and bundles
organized in a more regular fashion when compared to PBS or PRP group with marked induction of neovascularization in the wound area.
Overall, the present invention provides a cell-free conditioned MSC culture medium, which has unique functionality in skin and hair regeneration. Also, particularly, a novel and inventive method of MSC culturing is provided which is superior than known methods in the art.
Claims
1. A cell-free conditioned cell culture medium comprising: a. at least a protein selected from the group consisting of collagen alpha-l(l), collagen alpha-2, type IV collagenase isoform 2, collagen alpha-l(lll), transforming growth factor-beta induced protein ig-hB, and combinations thereof; b. at least a mi-RNA selected from the group consisting of hsa-miR-21-5p, hsa-miR- 3191-3p, hsa-miR-100-5p, hsa-miR-let-7i-5p, hsa-miR-4682-3p, and combinations thereof, wherein the medium is serum starved cell culture medium, wherein the fold change in at least a protein is 10-95-fold more than in serum free plain medium and fold change in at least a mi-RNA is 1.5-4-fold less than in serum fed cell culture medium.
2. The medium as claimed in claim 1, wherein said medium is obtained from a mesenchymal stromal cell (MSC) culture.
3. The medium as claimed in claim 2, wherein the MSC is derived from tissue selected from the group consisting of adipose tissue, dental pulp, mobilized peripheral blood, birth derived tissue, and placenta tissue, preferably placenta tissue.
4. The medium as claimed in claim 1, wherein the cell media is serum starved for 12-20 hours, preferably 16 hours.
5. The medium as claimed in claim 1, wherein the medium is obtained by a method as claimed in claim 6.
6. A method of preparing a conditioned cell culture medium, the method comprising: (i) obtaining an enriched population of Mesenchymal Stromal Cells (MSCs); (ii) seeding and culturing said enriched population of MSCs; and (iii) collecting the cell culture medium, wherein step (i) comprises: a. contacting at least a tissue with media comprising collagenase type 1 and collagenase type 2, wherein collagenase 1 weight concentration in said media is
in the range of 0.04-0.1% and collagenase 2 weight concentration in said media is in the range of 0.04-0.1%; and b. isolating enriched fraction of MSCs.
7. The method as claimed in claim 6, wherein said tissue is selected from the group consisting of adipose tissue, dental pulp tissue, mobilized peripheral blood, birth derived tissue, and placenta tissue, preferably placenta tissue.
8. The method as claimed in claim 6, wherein step (ia) is carried out for 20-40 minutes at 33- 39°C, preferably 37°C.
9. The method as claimed in claim 6, wherein step (ia) is devoid of trypsin.
10. The method as claimed in claim 6, wherein in step (ii) after seeding, MSC confluence of 70-80% is achieved in 20-25 days at passage 0.
11. The method as claimed in claim 6, wherein said MSC purity in the MSC culture of step (ii) is in the range of 90-99%, preferably 98% at passage 3.
12. The method as claimed in claim 6, wherein in step (ii) the MSC are passaged for up to at least 15 times.
13. The method as claimed in claim 6, wherein the conditioned cell culture medium is collected from serum starved media, wherein the media is starved of serum for at least 12-20 hours, preferably 16 hours.
14. Cell-free conditioned cell culture medium obtained by a process as claimed in claim 6.
15. Use of cell-free conditioned cell culture medium as claimed in claim 14 for use in tissue regeneration, vasculogenesis/angiogenesis, extra cellular matrix regeneration, or hair regeneration.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202141030280 | 2021-07-06 | ||
IN202141030280 | 2021-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023281524A1 true WO2023281524A1 (en) | 2023-01-12 |
Family
ID=84800410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2022/050492 WO2023281524A1 (en) | 2021-07-06 | 2022-05-26 | Placenta derived mesenchymal stromal cell secretome, process and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023281524A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017139795A1 (en) * | 2016-02-12 | 2017-08-17 | Cell Care Therapeutics | Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same |
US20190328792A1 (en) * | 2017-01-11 | 2019-10-31 | Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung | Mesenchymal stem cell-derived extracellular vesicles and their medical use |
RU2747024C1 (en) * | 2020-05-28 | 2021-04-23 | Общество с ограниченной ответственностью «Центр клеточных технологий Бирюч» | Composition with anti-inflammatory and immunosuppressive activity based on the secretome of multipotent mesenchymal stromal cells and a method for its preparation |
-
2022
- 2022-05-26 WO PCT/IN2022/050492 patent/WO2023281524A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017139795A1 (en) * | 2016-02-12 | 2017-08-17 | Cell Care Therapeutics | Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same |
US20190328792A1 (en) * | 2017-01-11 | 2019-10-31 | Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung | Mesenchymal stem cell-derived extracellular vesicles and their medical use |
RU2747024C1 (en) * | 2020-05-28 | 2021-04-23 | Общество с ограниченной ответственностью «Центр клеточных технологий Бирюч» | Composition with anti-inflammatory and immunosuppressive activity based on the secretome of multipotent mesenchymal stromal cells and a method for its preparation |
Non-Patent Citations (2)
Title |
---|
MATHEN CAROLINE, DSOUZA WILFRID: "In vitro and clinical evaluation of umbilical cord‐derived mesenchymal stromal cell‐conditioned media for hair regeneration", JOURNAL OF COSMETIC DERMATOLOGY, BLACKWELL SCIENCE, OXFORD, GB, vol. 21, no. 2, 1 February 2022 (2022-02-01), GB , pages 740 - 749, XP093023063, ISSN: 1473-2130, DOI: 10.1111/jocd.14114 * |
UDALAMATHTHA VINDYALANKIKA, KALUARACHCHI ATHULA, WIJERATNE SUMEDHA, UDAGAMA PREETHIVIDYA: "Therapeutic uses of post-partum tissue-derived mesenchymal stromal cell secretome", INDIAN JOURNAL OF MEDICAL RESEARCH, IN, vol. 152, no. 6, 1 December 2020 (2020-12-01), IN , pages 541 - 552, XP093023058, ISSN: 0971-5916, DOI: 10.4103/ijmr.IJMR_1450_18 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Conconi et al. | Homologous muscle acellular matrix seeded with autologous myoblasts as a tissue-engineering approach to abdominal wall-defect repair | |
KR20150020113A (en) | Mesenchymal stem cells treated mTOR/STAT3 signaling inhibitor having immuno-modulating activity and cell therapeutic agent for preventing or treating immune disease | |
KR20120095022A (en) | Cell therapy composition for preventing or treating graft-versus-host disease comprising mesenchymal stem cell and regulatory t cell | |
EP3756677A1 (en) | Erectile dysfunction therapeutic agent | |
JP2023060125A (en) | Treatment agent for epidermolysis bullosa | |
CN107073041A (en) | The multi-functional stem cell of Diabetic Skin Ulcer treatment | |
Melotti et al. | Could cold plasma act synergistically with allogeneic mesenchymal stem cells to improve wound skin regeneration in a large size animal model? | |
EP3656850A1 (en) | Mesenchymal-stem-cell induction agent | |
CN110903348B (en) | Small peptide for promoting wound healing and application thereof | |
KR20100097574A (en) | Cell composition for promoting hair growth | |
Ding et al. | Galectin-1-induced skeletal muscle cell differentiation of mesenchymal stem cells seeded on an acellular dermal matrix improves injured anal sphincter | |
JP2015227355A (en) | Keloid and hypertrophic scar curative therapeutic agent | |
JP2010500335A (en) | How to treat skin wounds | |
KR101656511B1 (en) | Conditioned culture medium cultivated with adipose-derived stem cells having improved hair growth and hair loss prevention activity and method for preparing the same | |
US7132279B2 (en) | Epidermal melanocyte culture formulations | |
WO2023281524A1 (en) | Placenta derived mesenchymal stromal cell secretome, process and uses thereof | |
KR101816964B1 (en) | Pharmaceutical adjuvant composition for treating damages of skin or blood vessel tissue | |
US20240216438A1 (en) | Composition containing function-reinforced stem cell for prevention or treatment of atopic dermatitis | |
US20200030253A1 (en) | Methods and compositions for treatment of body conditions | |
CN112773803A (en) | Application of small molecule in preparation of medicine for promoting skin wound healing | |
KR20160064954A (en) | Method for promoting growth of hair | |
KR101673318B1 (en) | Cell therapy composition for healing wounds comprising mesenchymal stem cell or the culture medium treated with silver nano particle | |
Zhou et al. | A novel experimental study on establish a myoblasts differentiated cell sheet using induced adipose-derived stem cell technology | |
KR20120139311A (en) | Composition producing lymph blood vessel | |
CN115569145B (en) | Application of polyguluronic acid propyl sulfate in preparation of products for preventing and treating atrial fibrillation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22837180 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22837180 Country of ref document: EP Kind code of ref document: A1 |